Wuxi Pharmatech (cayman) (NYSE:WX)

SHANGHAI, October 14, 2011 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development services company with operations in China and the United States, today announced the acquisition of Abgent, Inc., a provider of biological research reagent products and services based in Suzhou, China, and San Diego, California.

Founded in 2001, Abgent is already one of the world's largest manufacturers of antibody reagents for research use. The company maintains a comprehensive catalog of about 20,000 antibody products. Abgent also serves as the original manufacturer of antibodies distributed by large reagent suppliers. The company distributes its antibody reagent products by direct sales through its web portal and small sales force and through a network of distributors around the world. In addition to manufacturing antibodies, Abgent also develops and produces peptides and proteins for research and diagnostic applications. See More